Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages

Eriko Sada, Yasunobu Abe, Rie Ohba, Yoshimichi Tachikawa, Eriko Nagasawa, Motoaki Shiratsuchi, Ryoichi Takayanagi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Vitamin K2 (VK2) can improve cytopenia in some patients with myelodysplastic syndrome (MDS). Although it is well known that VK2 induces differentiation and apoptosis in acute myeloid leukemia (AML) cell lines, little is known about its effect on normal hematopoietic progenitors. The effects of VK2 on primary myeloid and erythroid progenitors were examined. Mobilized CD34-positive cells from peripheral blood were used for the examination of myeloid lineage cells, and erythroid progenitors purified from peripheral blood were used for erythroid lineage cells. VK2 upregulated the expressions of myeloid markers CD11b and CD14, and increased the mRNA expression levels of CCAAT/enhancer binding protein-α (C/EBPα) and PU.1 in myeloid progenitors. In erythroid progenitors, VK2 did not show a significant effect on differentiation. However, VK2 exhibited an anti-apoptotic effect on erythroid progenitors under erythropoietin depletion. This anti-apoptotic effect was restricted to normal erythroid progenitors and was not shown in erythroleukemic cell line AS-E2. Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors. These results indicate that SXR is involved in the effect of VK2 on myeloid progenitors. The major effect of VK2 on myeloid progenitors was promoting differentiation, whereas its anti-apoptotic effect seemed to be dominant in erythroid progenitors. Although the detailed mechanism of VK2's effect on differentiation or apoptosis of hematopoietic progenitors remains unknown, the effect of VK2 therapy in patients with MDS could be partly explained by these mechanisms.

Original languageEnglish
Pages (from-to)538-548
Number of pages11
JournalEuropean Journal of Haematology
Volume85
Issue number6
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Vitamin K 2
Apoptosis
Myelodysplastic Syndromes
Myeloid Cells
CCAAT-Enhancer-Binding Proteins
Cell Line
Erythroid Cells
Rifampin
Erythropoietin
Acute Myeloid Leukemia
Blood Cells

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages. / Sada, Eriko; Abe, Yasunobu; Ohba, Rie; Tachikawa, Yoshimichi; Nagasawa, Eriko; Shiratsuchi, Motoaki; Takayanagi, Ryoichi.

In: European Journal of Haematology, Vol. 85, No. 6, 12.2010, p. 538-548.

Research output: Contribution to journalArticle

Sada, Eriko ; Abe, Yasunobu ; Ohba, Rie ; Tachikawa, Yoshimichi ; Nagasawa, Eriko ; Shiratsuchi, Motoaki ; Takayanagi, Ryoichi. / Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages. In: European Journal of Haematology. 2010 ; Vol. 85, No. 6. pp. 538-548.
@article{4b55679294f640fca572aedb14592413,
title = "Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages",
abstract = "Vitamin K2 (VK2) can improve cytopenia in some patients with myelodysplastic syndrome (MDS). Although it is well known that VK2 induces differentiation and apoptosis in acute myeloid leukemia (AML) cell lines, little is known about its effect on normal hematopoietic progenitors. The effects of VK2 on primary myeloid and erythroid progenitors were examined. Mobilized CD34-positive cells from peripheral blood were used for the examination of myeloid lineage cells, and erythroid progenitors purified from peripheral blood were used for erythroid lineage cells. VK2 upregulated the expressions of myeloid markers CD11b and CD14, and increased the mRNA expression levels of CCAAT/enhancer binding protein-α (C/EBPα) and PU.1 in myeloid progenitors. In erythroid progenitors, VK2 did not show a significant effect on differentiation. However, VK2 exhibited an anti-apoptotic effect on erythroid progenitors under erythropoietin depletion. This anti-apoptotic effect was restricted to normal erythroid progenitors and was not shown in erythroleukemic cell line AS-E2. Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors. These results indicate that SXR is involved in the effect of VK2 on myeloid progenitors. The major effect of VK2 on myeloid progenitors was promoting differentiation, whereas its anti-apoptotic effect seemed to be dominant in erythroid progenitors. Although the detailed mechanism of VK2's effect on differentiation or apoptosis of hematopoietic progenitors remains unknown, the effect of VK2 therapy in patients with MDS could be partly explained by these mechanisms.",
author = "Eriko Sada and Yasunobu Abe and Rie Ohba and Yoshimichi Tachikawa and Eriko Nagasawa and Motoaki Shiratsuchi and Ryoichi Takayanagi",
year = "2010",
month = "12",
doi = "10.1111/j.1600-0609.2010.01530.x",
language = "English",
volume = "85",
pages = "538--548",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages

AU - Sada, Eriko

AU - Abe, Yasunobu

AU - Ohba, Rie

AU - Tachikawa, Yoshimichi

AU - Nagasawa, Eriko

AU - Shiratsuchi, Motoaki

AU - Takayanagi, Ryoichi

PY - 2010/12

Y1 - 2010/12

N2 - Vitamin K2 (VK2) can improve cytopenia in some patients with myelodysplastic syndrome (MDS). Although it is well known that VK2 induces differentiation and apoptosis in acute myeloid leukemia (AML) cell lines, little is known about its effect on normal hematopoietic progenitors. The effects of VK2 on primary myeloid and erythroid progenitors were examined. Mobilized CD34-positive cells from peripheral blood were used for the examination of myeloid lineage cells, and erythroid progenitors purified from peripheral blood were used for erythroid lineage cells. VK2 upregulated the expressions of myeloid markers CD11b and CD14, and increased the mRNA expression levels of CCAAT/enhancer binding protein-α (C/EBPα) and PU.1 in myeloid progenitors. In erythroid progenitors, VK2 did not show a significant effect on differentiation. However, VK2 exhibited an anti-apoptotic effect on erythroid progenitors under erythropoietin depletion. This anti-apoptotic effect was restricted to normal erythroid progenitors and was not shown in erythroleukemic cell line AS-E2. Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors. These results indicate that SXR is involved in the effect of VK2 on myeloid progenitors. The major effect of VK2 on myeloid progenitors was promoting differentiation, whereas its anti-apoptotic effect seemed to be dominant in erythroid progenitors. Although the detailed mechanism of VK2's effect on differentiation or apoptosis of hematopoietic progenitors remains unknown, the effect of VK2 therapy in patients with MDS could be partly explained by these mechanisms.

AB - Vitamin K2 (VK2) can improve cytopenia in some patients with myelodysplastic syndrome (MDS). Although it is well known that VK2 induces differentiation and apoptosis in acute myeloid leukemia (AML) cell lines, little is known about its effect on normal hematopoietic progenitors. The effects of VK2 on primary myeloid and erythroid progenitors were examined. Mobilized CD34-positive cells from peripheral blood were used for the examination of myeloid lineage cells, and erythroid progenitors purified from peripheral blood were used for erythroid lineage cells. VK2 upregulated the expressions of myeloid markers CD11b and CD14, and increased the mRNA expression levels of CCAAT/enhancer binding protein-α (C/EBPα) and PU.1 in myeloid progenitors. In erythroid progenitors, VK2 did not show a significant effect on differentiation. However, VK2 exhibited an anti-apoptotic effect on erythroid progenitors under erythropoietin depletion. This anti-apoptotic effect was restricted to normal erythroid progenitors and was not shown in erythroleukemic cell line AS-E2. Steroid and xenobiotic receptor (SXR), which was recently identified as a receptor of VK2, was expressed on myeloid progenitors, and the SXR agonist rifampicin (RIF) also upregulated CD11b and CD14 expressions on myeloid progenitors. These results indicate that SXR is involved in the effect of VK2 on myeloid progenitors. The major effect of VK2 on myeloid progenitors was promoting differentiation, whereas its anti-apoptotic effect seemed to be dominant in erythroid progenitors. Although the detailed mechanism of VK2's effect on differentiation or apoptosis of hematopoietic progenitors remains unknown, the effect of VK2 therapy in patients with MDS could be partly explained by these mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=78349289218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349289218&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2010.01530.x

DO - 10.1111/j.1600-0609.2010.01530.x

M3 - Article

C2 - 20887388

AN - SCOPUS:78349289218

VL - 85

SP - 538

EP - 548

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 6

ER -